The Importance of Promoting and Clarifying the Community Use of the New Therapeutic Weapons against COVID-19
Keywords:Antiviral Agents, COVID-19/drug therapy, SARS-CoV-2
Barreiro I, Matos M, de Oliveira M, Guerra D, Fonseca T, Abreu M, et al. Intrahospital protocol for the management of COVID-19 disease in adults. Acta Med Port. 2022;35:593-603.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao Weihang, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397-408.
Direção-Geral da Saúde. Norma nº 005-2022 de 28/05/2022. COVID-19 – Terapêutica farmacológica para a COVID-19. Lisboa: DGS; 2022.
World Health Organization. Therapeutics and COVID-19: living guideline, 14 July 2022. Geneva: WHO; 2022.
How to Cite
Copyright (c) 2022 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.